Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/469)
-
Patent number: 7547723Abstract: The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: June 20, 2005Date of Patent: June 16, 2009Inventor: Martin C. Hinz
-
Publication number: 20090143408Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: ApplicationFiled: November 26, 2008Publication date: June 4, 2009Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael EISSENSTAT, Dehui Duan, Ji-Hye Kang
-
Patent number: 7538138Abstract: Compounds of formula (I) or a pharmaceutically acceptable salts or prodrug thereof which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.Type: GrantFiled: April 8, 2005Date of Patent: May 26, 2009Assignee: Abbott LaboratoriesInventors: Marlon D. Cowart, Youssef L. Bennani, Ramin Faghih, Gregory A. Gfesser, Lawrence A. Black
-
Publication number: 20090130156Abstract: The present invention relates to a new formulation characterised by the presence of two components, one of which (A) possesses insecticidal, acaricidal, fungicidal, snailcidal or vermicidal activity and the other (B) exhibits synergistic activity with the first by enhancing its effectiveness, and in which the average release time of component (A) is 1 to 12 hours later than the average release time of component (B). The formulation is obtained by: a) separate microencapsulation of both components (A) and (B) within a multilayer system of specific polymers in which component (A) is in a more interior portion of the capsule than component (B), being separated from component (B) by a polymer layer of suitable thickness (FIG. 1); b) microencapsulation of both components within a single layer system (FIG. 2), combined with an immediate-release emulsion/microemulsion containing an additional amount of component (B).Type: ApplicationFiled: April 20, 2006Publication date: May 21, 2009Applicant: ENDURA S.P.A.Inventors: Valerio Borzatta, Oreste Picolo, Elisa Capparella
-
Publication number: 20090123387Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: January 9, 2009Publication date: May 14, 2009Inventor: Harry A. Dugger, III
-
Publication number: 20090123446Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.Type: ApplicationFiled: August 28, 2008Publication date: May 14, 2009Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Catherine Vicary, Scott Mellis
-
Publication number: 20090124613Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.Type: ApplicationFiled: November 7, 2008Publication date: May 14, 2009Inventors: Joanne J. Bronson, Andrew P. Degnan, William D. Schmitz
-
Publication number: 20090124687Abstract: The present invention relates to a compound having a leukotriene (particularly leukotriene B4) inhibitory action, and useful for the prophylaxis or treatment of diseases such as allergy, asthma, inflammation, cancer and the like.Type: ApplicationFiled: November 18, 2005Publication date: May 14, 2009Applicant: THE NEW INDUSTRY RESEARCH ORGANIZATIONInventors: Yoshitaka Oishi, Takehiko Yokomizo
-
Publication number: 20090125331Abstract: The present invention provides systems comprising two main components—a static and a dynamic component—that coupled with at least one interactive element of the systems permit providing information and support to a patient having a disease or disorder, responding to potential treatment issues of the patient, tracking a patient's treatment, and thereby improving patient compliance; as well as methods of using the systems, including methods of treating the patient and of ensuring the authenticity of a medication used by the patient.Type: ApplicationFiled: September 11, 2008Publication date: May 14, 2009Applicant: H. Lundbeck A/SInventors: Janne Pamsgaard, Jesper Lauridsen
-
Publication number: 20090118323Abstract: The present invention provides antitumor compounds of the formula (I); and antitumor methods.Type: ApplicationFiled: September 11, 2007Publication date: May 7, 2009Inventors: Mary Margaret Mader, Luisa Maria Martin-Cabrejas, Michael Enrico Richett
-
Publication number: 20090118301Abstract: The invention provides compounds useful for treating or effecting prophylaxis of cancers, particularly cervical cancer.Type: ApplicationFiled: October 30, 2008Publication date: May 7, 2009Applicant: Arbor Vita CorporationInventors: Peter S. Lu, Michael P. Belmares, Jingjing Wang, Johannes Schweizer, Aida A. Fantaye
-
Publication number: 20090118357Abstract: Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, —CnH2n-1, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R3 is selected from —CO—CH3, —NHOH, —OH, —OR6 in which R6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF3 or —CF2CF3, vinyl or allyl; R5, R7, R8 are hydrogen atoms; or R3 and R4, R4 and R5, or R7 and R8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.Type: ApplicationFiled: July 24, 2006Publication date: May 7, 2009Applicant: Giuliani International LimitedInventors: Giancarlo Naccari, Sergio Baroni
-
Publication number: 20090118157Abstract: The present invention provides a method for producing wine lactone, a method for producing intermediates that are usable in production of wine lactone, and techniques for the application of wine lactone. The method for producing the wine lactone (Compound (6)) of the present invention comprises the following steps (A) to (E): wherein R1 is a C1-4 lower alkyl group.Type: ApplicationFiled: September 10, 2004Publication date: May 7, 2009Applicant: San-Ei Gen F.F.I. Inc.Inventors: Mineko Omoto, Chiyoki Yukawa, Yoshiteru Nishijo
-
Patent number: 7524878Abstract: Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: April 30, 2004Date of Patent: April 28, 2009Assignee: The Institute for Pharmaceuticals Discovery LLCInventors: Darren Whitehouse, Shaojing Hu, Haiquan Fang, Michael C. Van Zandt
-
Patent number: 7524882Abstract: A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.Type: GrantFiled: July 25, 2003Date of Patent: April 28, 2009Assignee: Merck & Co., Inc.Inventors: Guo Q. Shi, Yong Zhang
-
Publication number: 20090105333Abstract: This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.Type: ApplicationFiled: May 22, 2007Publication date: April 23, 2009Inventors: Gunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
-
Patent number: 7521570Abstract: To provide highly safe therapeutic or preventive agents for hyperuricemia, more specifically uricosuric agents, which have potent uricosuric effect and do not cause grave hepatic disorder. Medicinal compositions for the treatment or prevention of hyperuricemia or diseases caused by hyperuricemia, which contain 6-hydroxybenzbromarone or salts thereof, and pharmaceutically acceptable carriers; uricosuric agents, xanthine oxidase inhibitors, and inhibitors against the uptake of uric acid in kidney, which contain 6-hydroxybenzbromarone or salts thereof; and a process for the production of 6-hydroxybenzbromarone.Type: GrantFiled: June 10, 2005Date of Patent: April 21, 2009Assignees: Torli Pharmaceutical Co., Ltd., Human Cell Systems, Inc.Inventors: Hitoshi Endou, Toshihiro Oikawa
-
Publication number: 20090099135Abstract: Embodiments of the present invention provide compositions for controlling a target pest including a pest control product and at least one active agent, wherein: the active agent can be capable of interacting with a receptor in the target pest; the pest control product can have a first activity against the target pest when applied without the active agent and the compositions can have a second activity against the target pest; and the second activity can be greater than the first activity.Type: ApplicationFiled: January 16, 2008Publication date: April 16, 2009Applicant: TyraTech, Inc.Inventor: Essam Enan
-
Publication number: 20090099169Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein R1, R2a, R2b, R2c, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.Type: ApplicationFiled: April 3, 2007Publication date: April 16, 2009Applicant: GLAXO GROUP LIMITEDInventors: Mairi Gibson, Adrian Hall, David Nigel Hurst, Derek Anthony Rawlings
-
Patent number: 7517908Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.Type: GrantFiled: May 20, 2005Date of Patent: April 14, 2009Assignee: Duke UniversityInventors: Ranga R. Krishnan, Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinova, Tatiana D. Sotnikova
-
Publication number: 20090093485Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).Type: ApplicationFiled: October 26, 2005Publication date: April 9, 2009Applicant: ASTRAZENECA ABInventors: Hakan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepisto
-
Publication number: 20090088469Abstract: Method for the preparation of citalopram comprising reaction of a compound of Formula (IV) wherein R is halogen, or CF3—(CF2)n—SO2—, n being 0 to 8, with a cyanide source in the presence of a palladium catalyst and a catalytic amount of Cu+ or Zn2+, or with Zn(CN)2 in the presence of a palladium catalyst.Type: ApplicationFiled: December 8, 2008Publication date: April 2, 2009Applicant: H. Lundbeck A/SInventors: Hans Petersen, Michael Harold Rock, Henrik Svane
-
Publication number: 20090087409Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, alType: ApplicationFiled: November 26, 2008Publication date: April 2, 2009Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20090088468Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.Type: ApplicationFiled: February 2, 2007Publication date: April 2, 2009Inventor: Nagesh R. Palepu
-
Publication number: 20090082392Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.Type: ApplicationFiled: April 15, 2008Publication date: March 26, 2009Inventors: Michael C. Van Zandt, Darren Whitehouse, Kerry Combs, Shaojing Hu
-
Publication number: 20090082434Abstract: Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.Type: ApplicationFiled: September 15, 2008Publication date: March 26, 2009Applicant: WyethInventors: Jonathan Laird Gross, Marla Jean Williams, Gary Paul Stack, Hong Gao, Dahul Zhou
-
Patent number: 7507839Abstract: Various divalent ligands based on khellinone derivatives are described. These derivatives can be useful in the modulation of potassium channel activity in cells, including among others Kv1.3 channels found in T-cells. The compounds may also be useful in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis.Type: GrantFiled: March 20, 2003Date of Patent: March 24, 2009Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Jonathan B. Baell, Heike Wulff, Andrew J. Harvey, Raymond S. Norton, George K. Chandy
-
Publication number: 20090076137Abstract: The present application describes deuterium-enriched dronedarone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090075938Abstract: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C?W, NR4, NC(?O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents -L-R3, in which L is a single bond or a linker group, additionally, R1, R3-R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent paiType: ApplicationFiled: February 9, 2007Publication date: March 19, 2009Inventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
-
Publication number: 20090076138Abstract: The present application describes deuterium-enriched darunavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090069417Abstract: The present invention relates to a method for the chemoprevention and treatment of cancer, by administering a pharmaceutical composition comprising a carotenoid derivative, such as a derivative of lycopene, a- and b-carotene, phytoene, phytofluene, lutein, zeaxanthin, ?- and ?-cryptoxanthin, canthaxanthin, astaxanthin, or other carotenoid. The carotenoid derivative is a carotenoid oxidation product, and is preferably an aldehyde derivative, a dialdehyde derivative or a ketone derivative. The carotenoid derivative can be a derivative of any naturally occurring carotenoid, such as those found in tomatoes and other fruits and vegetables.Type: ApplicationFiled: October 5, 2006Publication date: March 12, 2009Inventors: Yoav Sharoni, Joseph Levy, Yoram Sela, Zohar Nir
-
Publication number: 20090062382Abstract: The present invention provides a preventive or a remedy for penile erectile dysfunction, which promotes blood-flow in a penile sponge body over long time and thus induces erection while showing high safety without any adverse effect on a body as a whole, when externally administered to a penis. Use of a drug of the present invention enables to prevent or treat male penile erectile dysfunction and, at the same time, overcome a problem of female insertion impediment caused by increased resistance due to vaginal secretion disorder. Namely, a sexual life of patients (including aged persons) having coital dysfunction can be normalized and thus QOL can be improved.Type: ApplicationFiled: August 25, 2008Publication date: March 5, 2009Applicant: CARDIOVASCULAR INSTITUTE, LTD.Inventors: Yasumi UCHIDA, Yasuto Uchida, Haruko Uchida
-
Publication number: 20090060905Abstract: The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.Type: ApplicationFiled: July 30, 2008Publication date: March 5, 2009Applicant: GenfitInventors: Genevieve Martin, Sebastien Barradeau, Sakina Sayah-Jeanne
-
Patent number: 7498349Abstract: Aromatic compounds exemplified by exhibit antimicrobial activity.Type: GrantFiled: August 1, 2003Date of Patent: March 3, 2009Assignee: Genesoft Pharmaceuticals, Inc.Inventors: Roland W. Burli, Eldon E. Baird, Jacob A. Kaizerman, Dustin L. McMinn
-
Publication number: 20090054235Abstract: The present invention relates to novel benzoheterocyclylethylbenzamide derivatives of formula (I) in which the substituents are in the description, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions, and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.Type: ApplicationFiled: July 6, 2006Publication date: February 26, 2009Inventors: Darren Mansfield, Pierre-Yves Coqueron, Heiko Rieck, Philippe Desbordes, Alain Villier, Marie-Claire Grosjean-Cournoyer, Pierre Genix
-
Publication number: 20090047278Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.Type: ApplicationFiled: February 28, 2006Publication date: February 19, 2009Applicant: Eisai R & D Management Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Toshiaki Wakabayashi
-
Publication number: 20090048336Abstract: Escitalopram oxalate powders having definite particle size distribution parameters, processes for preparing the powders, and solid pharmaceutical formulations containing the powders.Type: ApplicationFiled: August 18, 2008Publication date: February 19, 2009Inventors: Naveen Kumar Kolla, Ravi Ram Elati, Srinivas Gangula
-
Publication number: 20090042875Abstract: The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more substituted heterocyclic compounds. The present invention further relates to articles of manufacture and kits comprising one or more substituted heterocyclic compounds.Type: ApplicationFiled: September 29, 2008Publication date: February 12, 2009Inventors: George W. Muller, Hon-Wah Man
-
Patent number: 7488752Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.Type: GrantFiled: October 5, 2005Date of Patent: February 10, 2009Assignee: Schering CorporationInventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia, Keith A. Eagen
-
Publication number: 20090035292Abstract: Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.Type: ApplicationFiled: August 1, 2008Publication date: February 5, 2009Inventors: John S. Kovach, Zhengping Zhuang
-
Publication number: 20090036309Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.Type: ApplicationFiled: February 6, 2008Publication date: February 5, 2009Inventors: John S. Kovach, Francis Johnson
-
Publication number: 20090029947Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.Type: ApplicationFiled: March 11, 2008Publication date: January 29, 2009Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
-
Publication number: 20090030073Abstract: A therapeutic agent for a malignant tumor containing a compound represented by the following formula (1) or (2): (wherein each of R1 and R2 represents a methyl group, or R1 and R2 may be linked together to form a methylene group; and R3 represents a hydrogen atom or a methoxy group).Type: ApplicationFiled: February 15, 2007Publication date: January 29, 2009Inventors: Takashi Suzuki, Yasuo Fujimoto, Taketo Uchiyama, Keiichi Tabata
-
Publication number: 20090023800Abstract: A cannabinoid receptor modulator containing a compound represented by Formula (I0) wherein, X is an oxygen atom, etc., R0 is an optionally substituted acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof.Type: ApplicationFiled: August 29, 2008Publication date: January 22, 2009Inventors: Shigenori Ohkawa, Tetsuya Tsukamoto, Yoshihiro Kiyota, Mika Goto, Shouzou Yamamoto, Masato Shimojou, Masaki Setou
-
Publication number: 20090023783Abstract: The invention relates to novel benzofuran derivatives, processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disordersType: ApplicationFiled: August 29, 2008Publication date: January 22, 2009Inventors: Chengzhi Zhang, Jacques Dumas, Gaetan H. Ladouceur, Qian Zhao, Martin Hentemann, Sharad K. Verma, Qingming Zhu, Rico C. Lavoie, Jianmei Fan, Barton Phillips
-
Publication number: 20090023798Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity.Type: ApplicationFiled: June 16, 2008Publication date: January 22, 2009Applicant: PHARMACYCLICS, INC.Inventors: Darren Magda, Zhong Wang
-
Publication number: 20090018161Abstract: The present invention provides a more effective gastrointestinal function promoter. The present invention also provides a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like. The present invention also provides a method for screening for a substance capable of promoting a gastrointestinal function. The present invention provides a gastrointestinal function promoter containing a T1R agonist as an active ingredient and a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like by administering a T1R agonist. The present invention also provides a method of screening for a substance capable of promoting a gastrointestinal function which method uses a cell expressing T1R receptor.Type: ApplicationFiled: May 2, 2008Publication date: January 15, 2009Applicant: AJINOMOTO CO. INC.Inventors: Tatsuro Tanaka, Hisayuki Uneyama, Shinichi Fujita, Saori Ogawa, Yusuke Amino, Seiji Shiraishi, Koichi Fujita, Tatsuhiro Yamada, Takashi Yamamoto, Takeshi Aihara, Manabu Suzuki
-
Patent number: 7476763Abstract: Novel cyclohexyl-1,4-diamine compounds corresponding to formula I: methods for their production, pharmaceutical formulations containing these compounds, methods of producing such pharmaceutical formulations and related methods of treating or inhibiting certain diseases or conditions.Type: GrantFiled: November 9, 2006Date of Patent: January 13, 2009Assignee: Gruenenthal GmbHInventors: Corinna Sundermann, Bernd Sundermann
-
Patent number: 7476690Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.Type: GrantFiled: June 21, 2006Date of Patent: January 13, 2009Assignee: Cephalon FranceInventors: Brigitte Lesur, Christophe Yue, Sophie Chasset, Olivier Renault
-
Publication number: 20090012081Abstract: An agent for promoting the proliferation or differentiation of a stem cell and/or neural progenitor cell, comprising a compound represented by Formula: wherein each of R1 and R2 is H, a hydrocarbon group or a heterocyclic group, or taken together with the adjacent carbon atom to form a ring, R3 is H, a hydrocarbon group or a heterocyclic group, W is a group represented by Formula: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted 5- to 7-membered nitrogen-containing heterocyclic ring, R4 is an acyl group having an aliphatic hydrocarbon group, which is substituted by an aromatic group and may have a further substitutent, or aromatic group, R5 is H, C1-6 alkyl or acyl, R4c is an aromatic group, an aliphatic hydrocarbon group or acyl, and X is O or S; Y is O, S or NH, Ring C is an optionally substituted benzene ring, or a salt or prodrug thereof is provided.Type: ApplicationFiled: December 14, 2007Publication date: January 8, 2009Applicant: Takeda Pharmaceutical Company Ltd.Inventors: Shigenori Okawa, Masaomi Miyamoto, Masahiro Okura